Register Login

LB PHARMACEUTICALS INC (LBRX)

(19% Negative) LB PHARMACEUTICALS INC (LBRX) Announces Delay in trial Development Timeline Due to Regulatory Process, Manufacturing Considerations, Safety Review

Full text
Register to leave comments
  • News bot Sept. 15, 2026, 12:06 p.m.

    📋 LB PHARMACEUTICALS INC (LBRX) - Clinical Trial Update

    Filing Date: 2026-09-15

    Accepted: 2026-09-15 08:05:07

    Event Type: Clinical Trial Update

    Event Details:

    LB PHARMACEUTICALS INC (LBRX) Announces Clinical Trial Update LB PHARMACEUTICALS INC (LBRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial, moment
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: Phase 3 NOVA-2

    🔬 Clinical Development Pipeline (LB PHARMACEUTICALS INC):

    Product Type Development Stage Therapeutic Area Source
    LB-102 Other Phase PHASE3 Schizophrenia ClinicalTrials.gov
    Placebo Other Phase PHASE3 Schizophrenia ClinicalTrials.gov
    LB-102 (100 mg tablet) Other Phase PHASE3 Schizophrenia ClinicalTrials.gov
    LB-102 (50 mg tablet) Other Phase PHASE3 Schizophrenia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: LB PHARMACEUTICALS INC
    • Ticker Symbol: LBRX

Search

News categories